The 5 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 31.00, with a high estimate of 75.00 and a low estimate of 24.00. The median estimate represents a +98.59% increase from the last price of 15.61.
The current consensus among 5 polled investment analysts is to Buy stock in EyePoint Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.52
Reporting Date Mar 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.